Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
NCT ID: NCT00940940
Last Updated: 2022-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
4 participants
INTERVENTIONAL
2009-10-31
2013-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Solid organ transplant recipients receive lifelong immunosuppression drugs and are at great risk of reactivation of all herpesviruses including the varicella zoster virus regardless of age. The vaccine has been shown to be effective in preventing shingles in the general population. The investigators' purpose is to determine how well the vaccine works in patients on renal replacement therapy and post-transplant.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ZOSTAVAX® in Renal Transplant Patients
NCT01137669
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
NCT06162494
Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients
NCT03685682
Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
NCT00005009
Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.
NCT02692066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Live attenuated herpes zoster vaccine
Zostavax (Live attenuated herpes zoster vaccine)
0.6 mL subcutaneous
Placebo
Placebo vaccine
0.65 mL subcutaneous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zostavax (Live attenuated herpes zoster vaccine)
0.6 mL subcutaneous
Placebo vaccine
0.65 mL subcutaneous
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Listed or will likely be listed for live donor kidney transplant within one month
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deepali Kumar, MD
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta Hospital
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DKUA-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.